维基百科
替尔泊肽
替尔泊肽(Tirzepatide)是由礼来公司开发的治疗II型糖尿病和肥胖的药物[7]。其商用品牌名为Mounjaro。该药物使用方式为皮下注射。
臨床資料 | |
---|---|
商品名 | Mounjaro |
其他名稱 | LY3298176, GIP/GLP-1 RA |
核准狀況 |
|
懷孕分級 | |
给药途径 | 皮下注射 |
藥物類別 | 抗糖尿病药,GLP-1受体激动剂 |
ATC碼 |
|
法律規範狀態 | |
法律規範 | |
藥物動力學數據 | |
生物利用度 | 80% |
血漿蛋白結合率 | 白蛋白 |
药物代谢 | Proteolytic cleavage, β-oxidation of fatty diacid section and amide hydrolysis |
生物半衰期 | 5 days |
排泄途徑 | Urine and faeces |
识别信息 | |
| |
CAS号 | 2023788-19-2 |
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
化学信息 | |
化学式 | C225H348N48O68 |
摩尔质量 | 4,813.53 g·mol−1 |
3D模型(JSmol) |
|
| |
|
常见的副作用包括恶心,呕吐,腹泻,食欲不振,便秘,腹痛。
禁忌症 编辑
替尔泊肽不适用于患有甲状腺髓质癌的病人。
参考文献 编辑
- ^ 1.0 1.1 Australian prescription medicine decision summaries: Mounjaro. Therapeutic Goods Administration. [28 February 2023]. (原始内容于5 February 2023).
- ^ Mounjaro tirzepatide 15 mg/0.5 mL solution for injection pre-filled pen (379334). Therapeutic Goods Administration. [28 February 2023]. (原始内容于3 January 2023).
- ^ Public Summary: Mounjaro tirzepatide 15 mg/0.5 mL solution for injection pre-filled pen. Therapeutic Goods Administration. [28 February 2023].
- ^ Notice: Multiple Additions to the Prescription Drug List (PDL) [2023-03-08]. Health Canada. 8 March 2023 [21 March 2023]. (原始内容于22 March 2023).
- ^ Summary Basis of Decision - Mounjaro. Health Canada. 17 March 2023 [24 April 2023]. (原始内容于25 April 2023).
- ^ Mounjaro- tirzepatide injection, solution. DailyMed. 13 May 2022 [27 May 2022]. (原始内容于3 July 2022).
- ^ 7.0 7.1 FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes. U.S. Food and Drug Administration (FDA) (新闻稿). 13 May 2022 [13 May 2022]. (原始内容于13 May 2022). 该来源属于公有领域,本文含有该来源内容。
- ^ Mounjaro EPAR. European Medicines Agency (EMA). 18 July 2022 [2 January 2023]. (原始内容于12 December 2022). Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.